ESMO – European Society for Medical Oncology shared a post on LinkedIn:
“In an in-depth exploration of the therapeutic landscape of advanced NSCLC, focusing on critical oncogenes such as EGFR, RAS/RAF, MET, and ERBB2, our expert panel will delve into the molecular mechanisms and clinical implications of these biomarkers, discussing the importance of comprehensive molecular profiling in identifying these mutations.
More posts featuring NSCLC.